RVLP News and Press, RVL Pharmaceuticals plc From 07/08/22

Gainers: Seritage Growth Properties ( SRG ) +72% . Aditxt ( ADTX ) +70% . Humanigen ( HGEN ) +35% . Clovis Oncology ( CLVS ) +30% . MyMD Pharmaceuticals ( MYMD ) +27% . Oramed Pharmaceuticals ( ORMP ) +26% . Kura ...

Citing preliminary financials, New Jersey-based RVL Pharmaceuticals ( NASDAQ: RVLP ) announced on Thursday that the company generated nearly $8.4M net product sales for its eye disease therapy Upneeq in 2Q 2022 implying a sequential growth of ~42%. Upneeq is indicated for ...

-- Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 -- -- Second quarter 2022 net product sales growth contributes to approximately $14.4 million in the six months ended June 30, 2...

BRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the Company’s Annual General Meeting. At the Annual General Meeting o...

RVL focused its initial launch of UPNEEQ for adults with acquired blepharoptosis on medical treatment. UPNEEQ's critical first quarter addressing the aesthetics side is now in the books. Despite positive UPNEEQ revenues, RVL is no more than a hold. For further details see: ...

The following slide deck was published by RVL Pharmaceuticals plc in conjunction with this event. For further details see: RVL Pharmaceuticals (RVLP) Investor Presentation - Slideshow

BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as foll...

RVL Pharmaceuticals plc (RVLP) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Brian Markison – Chief Executive Officer Mike DePetris – Interim Chief Financial Officer JD Schaub – Chief Operational Offi...

press release (NASDAQ:RVLP): Q1 GAAP EPS of -$0.08 beats by $0.13. Revenue of $21.4M beats by $14.6M. For further details see: GAAP EPS of -$0.08 beats by $0.13, revenue of $21.4M beats by $14.6M

First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 Reaffirms fourth quarter 2...